Biogen losing traction For Biogen’s ill-fated Alzheimer’s disease drug Aduhelm, a narrow Medicare reimbursement policy is taking a toll beyond sales and on the company’s clinical development plan. Biogen has pulled the plug on the observational ICARE AD trial, which was meant to collect real-world data on Aduhelm’s use in the U.S., according to an update posted Tuesday on ClinicalTrials.gov. A Biogen spokesperson confirmed the status to Fierce Pharma.
The termination comes as a result of the national coverage policy, Biogen said on the clinical trial registry. “t is expected there will be limited [Aduhelm] prescription and usage in routine clinical practice, making the study not feasible for enrollment.”